Nasopharyngeal Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Nasopharyngeal Cancer – Pipeline Review, H2 2016’, provides an overview of the Nasopharyngeal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer

The report reviews pipeline therapeutics for Nasopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Nasopharyngeal Cancer therapeutics and enlists all their major and minor projects

The report assesses Nasopharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories, LLC

Ambrx, Inc.

arGEN-X BV

Atara Biotherapeutics, Inc.

AVEO Pharmaceuticals, Inc.

Betta Pharmaceuticals Co. Ltd.

BioDiem Ltd

Biomics Biotechnologies Co., Ltd.

Celgene Corporation

Cell Medica Limited

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Lakewood-Amedex Inc

Merck & Co., Inc.

Merck KGaA

Molecular Partners AG

Novartis AG

Ono Pharmaceutical Co., Ltd.

Pharmacyclics, Inc.

Sapvax

Tessa Therapeutics Pte Ltd

Theravectys SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Nasopharyngeal Cancer Overview 11

Therapeutics Development 12

Pipeline Products for Nasopharyngeal Cancer - Overview 12

Pipeline Products for Nasopharyngeal Cancer - Comparative Analysis 13

Nasopharyngeal Cancer - Therapeutics under Development by Companies 14

Nasopharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 16

Nasopharyngeal Cancer - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Nasopharyngeal Cancer - Products under Development by Companies 20

Nasopharyngeal Cancer - Products under Investigation by Universities/Institutes 22

Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 23

Advenchen Laboratories, LLC 23

Ambrx, Inc. 24

arGEN-X BV 25

Atara Biotherapeutics, Inc. 26

AVEO Pharmaceuticals, Inc. 27

Betta Pharmaceuticals Co. Ltd. 28

BioDiem Ltd 29

Biomics Biotechnologies Co., Ltd. 30

Celgene Corporation 31

Cell Medica Limited 32

F. Hoffmann-La Roche Ltd. 33

GlaxoSmithKline Plc 34

Lakewood-Amedex Inc 35

Merck & Co., Inc. 36

Merck KGaA 37

Molecular Partners AG 38

Novartis AG 39

Ono Pharmaceutical Co., Ltd. 40

Pharmacyclics, Inc. 41

Sapvax 42

Tessa Therapeutics Pte Ltd 43

Theravectys SA 44

Nasopharyngeal Cancer - Therapeutics Assessment 45

Assessment by Monotherapy Products 45

Assessment by Target 46

Assessment by Mechanism of Action 48

Assessment by Route of Administration 50

Assessment by Molecule Type 52

Drug Profiles 54

abexinostat hydrochloride - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

apatinib - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

ARGX-110 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

atezolizumab - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

avelumab - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

azacitidine - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

baltaleucel-T - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Cellular Immunotherapy for Multiple Sclerosis - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Cellular Immunotherapy for Oncology - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Cellular Immunotherapy for Oncology - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

Cellular Immunotherapy for Solid Tumor and Central Nervous System Disorders - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

DC-120 - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

EBV-nRNA - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

Epstein-Barr virus vaccine - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

ficlatuzumab - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

GSK-2849330 - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

icotinib hydrochloride - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

JS-001 - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

LAG-525 - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

MP-0250 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

MVA vaccine - Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

NEO-212 - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

nimotuzumab - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

nivolumab - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

PDR-001 - Drug Profile 147

Product Description 147

Mechanism Of Action 147

R&D Progress 147

pembrolizumab - Drug Profile 148

Product Description 148

Mechanism Of Action 148

R&D Progress 148

RO-5203280 - Drug Profile 178

Product Description 178

Mechanism Of Action 178

R&D Progress 178

Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile 179

Product Description 179

Mechanism Of Action 179

R&D Progress 179

SV-638 - Drug Profile 180

Product Description 180

Mechanism Of Action 180

R&D Progress 180

TT-10 - Drug Profile 181

Product Description 181

Mechanism Of Action 181

R&D Progress 181

Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 182

Product Description 182

Mechanism Of Action 182

R&D Progress 182

Vaccine for Oncology - Drug Profile 183

Product Description 183

Mechanism Of Action 183

R&D Progress 183

Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile 184

Product Description 184

Mechanism Of Action 184

R&D Progress 184

Nasopharyngeal Cancer - Dormant Projects 185

Nasopharyngeal Cancer - Discontinued Products 186

Nasopharyngeal Cancer - Product Development Milestones 187

Featured News & Press Releases 187

Jun 23, 2016: Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) 187

Jun 06, 2016: Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate 187

May 18, 2016: Atara Bio Announces Presentation of Clinical Data from EBV-CT Product Candidate at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 188

Apr 19, 2016: Atara Biotherapeutics Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor 188

Mar 16, 2016: Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research Annual Meeting 189

Sep 26, 2015: New Findings Show Anti-Tumor Activity of KEYTRUDA in Patients with Advanced Nasopharyngeal Carcinoma 190

Sep 10, 2015: U.S. FDA grants Fast Track Designation to Tessa Therapeutics’ TT10 EB-VST for the treatment of Head and Neck Cancers 191

Mar 27, 2015: U.S. FDA approves Tessa Therapeutic’s IND application to begin Phase III trial involving Adoptive T cell therapy on Nasopharyngeal Cancer 191

Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 191

Appendix 193

Methodology 193

Coverage 193

Secondary Research 193

Primary Research 193

Expert Panel Validation 193

Contact Us 193

Disclaimer 194

List of Tables

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, H2 2016 12

Number of Products under Development for Nasopharyngeal Cancer – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Investigation by Universities/Institutes, H2 2016 22

Nasopharyngeal Cancer – Pipeline by Advenchen Laboratories, LLC, H2 2016 23

Nasopharyngeal Cancer – Pipeline by Ambrx, Inc., H2 2016 24

Nasopharyngeal Cancer – Pipeline by arGEN-X BV, H2 2016 25

Nasopharyngeal Cancer – Pipeline by Atara Biotherapeutics, Inc., H2 2016 26

Nasopharyngeal Cancer – Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 27

Nasopharyngeal Cancer – Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 28

Nasopharyngeal Cancer – Pipeline by BioDiem Ltd, H2 2016 29

Nasopharyngeal Cancer – Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016 30

Nasopharyngeal Cancer – Pipeline by Celgene Corporation, H2 2016 31

Nasopharyngeal Cancer – Pipeline by Cell Medica Limited, H2 2016 32

Nasopharyngeal Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 33

Nasopharyngeal Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 34

Nasopharyngeal Cancer – Pipeline by Lakewood-Amedex Inc, H2 2016 35

Nasopharyngeal Cancer – Pipeline by Merck & Co., Inc., H2 2016 36

Nasopharyngeal Cancer – Pipeline by Merck KGaA, H2 2016 37

Nasopharyngeal Cancer – Pipeline by Molecular Partners AG, H2 2016 38

Nasopharyngeal Cancer – Pipeline by Novartis AG, H2 2016 39

Nasopharyngeal Cancer – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 40

Nasopharyngeal Cancer – Pipeline by Pharmacyclics, Inc., H2 2016 41

Nasopharyngeal Cancer – Pipeline by Sapvax, H2 2016 42

Nasopharyngeal Cancer – Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 43

Nasopharyngeal Cancer – Pipeline by Theravectys SA, H2 2016 44

Assessment by Monotherapy Products, H2 2016 45

Number of Products by Stage and Target, H2 2016 47

Number of Products by Stage and Mechanism of Action, H2 2016 49

Number of Products by Stage and Route of Administration, H2 2016 51

Number of Products by Stage and Molecule Type, H2 2016 53

Nasopharyngeal Cancer – Dormant Projects, H2 2016 185

Nasopharyngeal Cancer – Discontinued Products, H2 2016 186

List of Figures

List of Figures

Number of Products under Development for Nasopharyngeal Cancer, H2 2016 12

Number of Products under Development for Nasopharyngeal Cancer – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Products, H2 2016 19

Assessment by Monotherapy Products, H2 2016 45

Number of Products by Top 10 Targets, H2 2016 46

Number of Products by Stage and Top 10 Targets, H2 2016 46

Number of Products by Top 10 Mechanism of Actions, H2 2016 48

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 48

Number of Products by Routes of Administration, H2 2016 50

Number of Products by Stage and Routes of Administration, H2 2016 50

Number of Products by Molecule Types, H2 2016 52

Number of Products by Stage and Molecule Types, H2 2016 52

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports